{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:30:05Z","timestamp":1793464205569,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"University of Basel","id":[{"id":"https:\/\/ror.org\/02s6k3f65","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>\n                    Morbus Stargardt (STGD1) ist die h\u00e4ufigste heredit\u00e4re Makuladystrophie. STGD1, verursacht durch biallelische Varianten im\n                    <jats:italic>ABCA4<\/jats:italic>\n                    -Gen, geht mit einer St\u00f6rung des Retinoidtransports in den Photorezeptoren einher. Infolge der gest\u00f6rten Retinoid-Clearance kommt es zur Akkumulation von Lipofuszin im retinalen Pigmentepithel (RPE), die oxidativen Stress, Komplementaktivierung und eine progressive Degeneration von RPE und Photorezeptoren verursacht. Trotz erheblicher Fortschritte im Verst\u00e4ndnis der zugrunde liegenden pathophysiologischen Mechanismen steht bislang keine zugelassene kausale Therapie zur Verf\u00fcgung. Es gibt jedoch mehrere vielversprechende pharmakologische Therapieans\u00e4tze in der pr\u00e4klinischen und klinischen Entwicklung, die auf verschiedene Stoffwechselschritte in und um den Sehzyklus abzielen. Der vorliegende Beitrag fasst die genetischen und pathophysiologischen Grundlagen von Morbus Stargardt zusammen und gibt einen \u00dcberblick \u00fcber m\u00f6gliche Lebensstilinterventionen sowie pharmakologische Therapiestrategien. Diese Fortschritte k\u00f6nnten in naher Zukunft in krankheitsmodifizierenden Therapien m\u00fcnden, was die Bedeutung einer fr\u00fchzeitigen Diagnose und der \u00dcberweisung an spezialisierte Zentren unterstreicht.\n                  <\/jats:p>","DOI":"10.1007\/s00347-026-02525-6","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:20:57Z","timestamp":1790259657000},"page":"857-864","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Morbus Stargardt: Genetik, molekulare Mechanismen, m\u00f6gliche Lebensstilinterventionen und Pharmakotherapie","Stargardt disease: genetics, molecular mechanisms, potential lifestyle interventions and pharmacotherapy"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1718-8612","authenticated-orcid":false,"given":"Theresa","family":"Lipsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Dithmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno J\u00f6rn","family":"Bolz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Duncker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Fleckenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Charbel Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Gerth-Kahlert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moreno","family":"Menghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ditta","family":"Zobor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Feltgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Pfau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Pfau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"2525_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/978-3-319-95046-4_27","volume":"1085","author":"SH Tsang","year":"2018","unstructured":"Tsang\u00a0SH, Sharma\u00a0T (2018) Stargardt Disease. Adv Exp Med Biol 1085:139\u2013151. https:\/\/doi.org\/10.1007\/978-3-319-95046-4_27","journal-title":"Adv Exp Med Biol"},{"key":"2525_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/J.PRETEYERES.2021.101036","volume":"89","author":"RS Molday","year":"2022","unstructured":"Molday\u00a0RS, Garces\u00a0FA, Scortecci\u00a0JF, Molday\u00a0LL (2022) Structure and function of ABCA4 and its role in the visual cycle and Stargardt macular degeneration. Prog Retin Eye Res 89:101036. https:\/\/doi.org\/10.1016\/J.PRETEYERES.2021.101036","journal-title":"Prog Retin Eye Res"},{"key":"2525_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS26147006","author":"K Dayma","year":"2025","unstructured":"Dayma\u00a0K, Rajanala\u00a0K, Upadhyay\u00a0A (2025) Stargardt\u2019s Disease: Molecular Pathogenesis and Current Therapeutic Landscape. Int J Mol Sci. https:\/\/doi.org\/10.3390\/IJMS26147006","journal-title":"Int J Mol Sci"},{"key":"2525_CR4","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/NG0397-236","volume":"15","author":"R Allikmets","year":"1997","unstructured":"Allikmets\u00a0R, Singh\u00a0N, Sun\u00a0H et\u00a0al (1997) A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet 15:236\u2013246. https:\/\/doi.org\/10.1038\/NG0397-236","journal-title":"Nat Genet"},{"key":"2525_CR5","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/BS.PMBTS.2015.06.008","volume":"134","author":"RS Molday","year":"2015","unstructured":"Molday\u00a0RS (2015) Insights into the Molecular Properties of ABCA4 and Its Role in the Visual Cycle and Stargardt Disease. Prog Mol Biol Transl Sci 134:415\u2013431. https:\/\/doi.org\/10.1016\/BS.PMBTS.2015.06.008","journal-title":"Prog Mol Biol Transl Sci"},{"key":"2525_CR6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/HMG\/DDH048","volume":"13","author":"AV Cideciyan","year":"2004","unstructured":"Cideciyan\u00a0AV, Aleman\u00a0TS, Swider\u00a0M et\u00a0al (2004) Mutations in ABCA4 result in accumulation of lipofuscin before slowing of the retinoid cycle: a reappraisal of the human disease sequence. Hum Mol Genet 13:525\u2013534. https:\/\/doi.org\/10.1093\/HMG\/DDH048","journal-title":"Hum Mol Genet"},{"key":"2525_CR7","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/J.AJO.2020.08.042","volume":"222","author":"PL M\u00fcller","year":"2021","unstructured":"M\u00fcller\u00a0PL, Gliem\u00a0M, McGuinnes\u00a0M et\u00a0al (2021) Quantitative Fundus Autofluorescence in ABCA4-Related Retinopathy -Functional Relevance and Genotype-Phenotype Correlation. Am J Ophthalmol 222:340\u2013350. https:\/\/doi.org\/10.1016\/J.AJO.2020.08.042","journal-title":"Am J Ophthalmol"},{"key":"2525_CR8","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1167\/IOVS.13-13624","volume":"55","author":"TR Burke","year":"2014","unstructured":"Burke\u00a0TR, Duncker\u00a0T, Woods\u00a0RL et\u00a0al (2014) Quantitative fundus autofluorescence in recessive Stargardt disease. Invest Ophthalmol Vis Sci 55:2841\u20132852. https:\/\/doi.org\/10.1167\/IOVS.13-13624","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2525_CR9","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1096\/FJ.201901784RR","volume":"34","author":"Y Fang","year":"2020","unstructured":"Fang\u00a0Y, Tschulakow\u00a0A, Taubitz\u00a0T et\u00a0al (2020) Fundus autofluorescence, spectral-domain optical coherence tomography, and histology correlations in a\u00a0Stargardt disease mouse model. FASEB J 34:3693\u20133714. https:\/\/doi.org\/10.1096\/FJ.201901784RR","journal-title":"FASEB J"},{"key":"2525_CR10","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/BJO.65.5.359","volume":"65","author":"G Fish","year":"1981","unstructured":"Fish\u00a0G, Grey\u00a0R, Sehmi\u00a0KS, Bird\u00a0AC (1981) The dark choroid in posterior retinal dystrophies. Br J Ophthalmol 65:359. https:\/\/doi.org\/10.1136\/BJO.65.5.359","journal-title":"Br J Ophthalmol"},{"key":"2525_CR11","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0161-6420(91)32196-1","volume":"98","author":"GA Fishman","year":"1991","unstructured":"Fishman\u00a0GA, Farbman\u00a0JS, Alexander\u00a0KR (1991) Delayed rod dark adaptation in patients with Stargardt\u2019s disease. Ophthalmology 98:957\u2013962. https:\/\/doi.org\/10.1016\/S0161-6420(91)32196-1","journal-title":"Ophthalmology"},{"key":"2525_CR12","doi-asserted-by":"publisher","first-page":"22276","DOI":"10.1074\/JBC.M111.329235","volume":"287","author":"NP Boyer","year":"2012","unstructured":"Boyer\u00a0NP, Higbee\u00a0D, Currin\u00a0MB et\u00a0al (2012) Lipofuscin and N\u2011retinylidene-N-retinylethanolamine (A2E) accumulate in retinal pigment epithelium in absence of light exposure: their origin is 11-cis-retinal. J\u00a0Biol Chem 287:22276\u201322286. https:\/\/doi.org\/10.1074\/JBC.M111.329235","journal-title":"J Biol Chem"},{"key":"2525_CR13","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1167\/IOVS.07-1470","volume":"49","author":"RA Radu","year":"2008","unstructured":"Radu\u00a0RA, Yuan\u00a0Q, Hu\u00a0J et\u00a0al (2008) Accelerated Accumulation of Lipofuscin Pigments in the RPE of a Mouse Model for ABCA4-Mediated Retinal Dystrophies following Vitamin A Supplementation. Invest Ophthalmol Vis Sci 49:3821\u20133829. https:\/\/doi.org\/10.1167\/IOVS.07-1470","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2525_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-3-031-27681-1_3","volume":"1415","author":"R Arunkumar","year":"2023","unstructured":"Arunkumar\u00a0R, Bernstein\u00a0PS (2023) Macular Pigment Carotenoids and Bisretinoid A2E. Adv Exp Med Biol 1415:15\u201320. https:\/\/doi.org\/10.1007\/978-3-031-27681-1_3","journal-title":"Adv Exp Med Biol"},{"key":"2525_CR15","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/J.AJO.2015.02.004","volume":"159","author":"MM Teussink","year":"2015","unstructured":"Teussink\u00a0MM, Lee\u00a0MD, Smith\u00a0RT et\u00a0al (2015) The effect of light deprivation in patients with Stargardt disease. Am J Ophthalmol 159:964\u2013972.e2. https:\/\/doi.org\/10.1016\/J.AJO.2015.02.004","journal-title":"Am J Ophthalmol"},{"key":"2525_CR16","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2147\/OPTH.S10049","volume":"4","author":"G Querques","year":"2010","unstructured":"Querques\u00a0G, Benlian\u00a0P, Chanu\u00a0B et\u00a0al (2010) DHA supplementation for late onset Stargardt disease: NAT\u20113 study. Clin Ophthalmol 4:575\u2013580. https:\/\/doi.org\/10.2147\/OPTH.S10049","journal-title":"Clin Ophthalmol"},{"key":"2525_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000001213","author":"N Barthelemy","year":"2026","unstructured":"Barthelemy\u00a0N, Lee\u00a0W, Gregori\u00a0NZ et\u00a0al (2026) Nutritional supplements: current evidence for retinitis pigmentosa and Stargardt disease. Curr Opin Ophthalmol. https:\/\/doi.org\/10.1097\/ICU.0000000000001213","journal-title":"Curr Opin Ophthalmol"},{"key":"2525_CR18","unstructured":"New Hope for People Living with a\u00a0Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase\u00a03 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease | Belite Bio, Inc. https:\/\/investors.belitebio.com\/news-releases\/news-release-details\/new-hope-people-living-disease-once-deemed-untreatable-belite. Accessed 23\u00a0Feb 2026"},{"key":"2525_CR19","doi-asserted-by":"publisher","first-page":"8415","DOI":"10.1073\/PNAS.1506960112","volume":"112","author":"PC Issa","year":"2015","unstructured":"Issa\u00a0PC, Barnard\u00a0AR, Herrmann\u00a0P et\u00a0al (2015) Rescue of the Stargardt phenotype in Abca4 knockout mice through inhibition of vitamin A dimerization. Proc Natl Acad Sci U S A 112:8415\u20138420. https:\/\/doi.org\/10.1073\/PNAS.1506960112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2525_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/JCM12196229","author":"L Wang","year":"2023","unstructured":"Wang\u00a0L, Shah\u00a0SM, Mangwani-Mordani\u00a0S, Gregori\u00a0NZ (2023) Updates on Emerging Interventions for Autosomal Recessive ABCA4-Associated Stargardt Disease. J\u00a0Clin Med. https:\/\/doi.org\/10.3390\/JCM12196229","journal-title":"J Clin Med"},{"key":"2525_CR21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/J.FREERADBIOMED.2022.02.025","volume":"182","author":"Y Fang","year":"2022","unstructured":"Fang\u00a0Y, Taubitz\u00a0T, Tschulakow\u00a0AV et\u00a0al (2022) Removal of RPE lipofuscin results in rescue from retinal degeneration in a\u00a0mouse model of advanced Stargardt disease: Role of reactive oxygen species. Free Radic Biol Med 182:132\u2013149. https:\/\/doi.org\/10.1016\/J.FREERADBIOMED.2022.02.025","journal-title":"Free Radic Biol Med"},{"key":"2525_CR22","first-page":"2205","volume":"65","author":"T Peters","year":"2024","unstructured":"Peters\u00a0T, Stingl\u00a0K, Klein\u00a0W et\u00a0al (2024) Remofuscin slows retinal thinning in Stargardt Disease (STGD1) \u2013 results from the Stargardt Remofuscin Treatment Trial (STARTT) a 2\u2011year placebo-controlled study. Invest Ophthalmol Vis Sci 65:2205\u20132205","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2525_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0124940","author":"C Bavik","year":"2015","unstructured":"Bavik\u00a0C, Henry\u00a0SH, Zhang\u00a0Y et\u00a0al (2015) Visual Cycle Modulation as an Approach toward Preservation of Retinal Integrity. PLoS One. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0124940","journal-title":"PLoS One"},{"key":"2525_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1136\/BJOPHTHALMOL-2020-317712","volume":"106","author":"R Kubota","year":"2022","unstructured":"Kubota\u00a0R, Birch\u00a0DG, Gregory\u00a0JK, Koester\u00a0JM (2022) Randomised study evaluating the pharmacodynamics of emixustat hydrochloride in subjects with macular atrophy secondary to Stargardt disease. Br J Ophthalmol 106:403\u2013408. https:\/\/doi.org\/10.1136\/BJOPHTHALMOL-2020-317712","journal-title":"Br J Ophthalmol"},{"key":"2525_CR25","doi-asserted-by":"publisher","first-page":"4742","DOI":"10.1073\/PNAS.0737855100","volume":"100","author":"RA Radu","year":"2003","unstructured":"Radu\u00a0RA, Mata\u00a0NL, Nusinowitz\u00a0S et\u00a0al (2003) Treatment with isotretinoin inhibits lipofuscin accumulation in a\u00a0mouse model of recessive Stargardt\u2019s macular degeneration. Proc Natl Acad Sci U S A 100:4742\u20134747. https:\/\/doi.org\/10.1073\/PNAS.0737855100","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2525_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2025.2505530","author":"T Tao","year":"2025","unstructured":"Tao\u00a0T, Du\u00a0GL, Zhang\u00a0ZJ et\u00a0al (2025) Unveiling the hidden ocular risks of isotretinoin: a comprehensive FAERS-Based analysis. Expert Opin Drug Saf. https:\/\/doi.org\/10.1080\/14740338.2025.2505530","journal-title":"Expert Opin Drug Saf"},{"key":"2525_CR27","doi-asserted-by":"publisher","first-page":"10475","DOI":"10.1073\/PNAS.1802724115\/-\/DCSUPPLEMENTAL","volume":"115","author":"L Xu","year":"2018","unstructured":"Xu\u00a0L, Kong\u00a0L, Wang\u00a0J, Ash\u00a0JD (2018) Stimulation of AMPK prevents degeneration of photoreceptors and the retinal pigment epithelium. Proc Natl Acad Sci U S A 115:10475\u201310480. https:\/\/doi.org\/10.1073\/PNAS.1802724115\/-\/DCSUPPLEMENTAL","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2525_CR28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/14712598.2019.1575358","volume":"19","author":"E Kassa","year":"2019","unstructured":"Kassa\u00a0E, Ciulla\u00a0TA, Hussain\u00a0RM, Dugel\u00a0PU (2019) Complement inhibition as a therapeutic strategy in retinal disorders. Expert Opin Biol Ther 19:335\u2013342. https:\/\/doi.org\/10.1080\/14712598.2019.1575358","journal-title":"Expert Opin Biol Ther"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02525-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-026-02525-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02525-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:35:52Z","timestamp":1793460952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-026-02525-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2525"],"URL":"https:\/\/doi.org\/10.1007\/s00347-026-02525-6","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.\u00a0Lipsky, S.\u00a0Dithmar, V.\u00a0Peter, P.\u00a0Charbel Issa, M.\u00a0Menghini, F.\u00a0Romano und D.\u00a0Zobor geben an, dass kein Interessenkonflikt besteht. Finanzielle Interessenskonflikte: G.\u00a0Ansari: BrightFocus, iCare, F.\u00a0Hoffmann-La Roche; H.J.\u00a0Bolz: Angestellter bei Bioscientia; T.\u00a0Duncker: Alimera, Bayer, Heidelberg Engineering, Novartis, F.\u00a0Hoffmann-La Roche, STAAR Surgical; M.\u00a0Fleckenstein: iCare; C.\u00a0Gerth-Kahlert: Amgen (Honoraria f\u00fcr Advisory Board, gezahlt an Arbeitgeber USZ), Velux Stiftung; N.\u00a0Feltgen: AbbVie, Apellis, Bayer, Novartis, F.\u00a0Hoffmann-La Roche; K.\u00a0Pfau: iCare, Daiichi Sankyo, Bayer, Heidelberg Engineering, F.\u00a0Hoffmann-La Roche, Inozyme; M.\u00a0Pfau: BrightFocus, iCare, Angestellter bei F.\u00a0Hoffmann-La Roche.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}